Drugs / LCAR-HL30
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06494371 | Jul 2024 → May 2026 overdue | Hodgkins lymphoma, anaplastic large cell lymphoma | Ruijin Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LCAR-HL30 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06494371 ↗ |
| Route | Other | “will receive LCAR-HL30 infusion.” NCT06494371 ↗ |